The most recent development would greatly reduce the cost under the president’s Most Favored Nation prescription drug pricing policy.
President Donald Trump announced that a deal has been reached with Novo Nordisk and Eli Lilly to lower the price of obesity and diabetes drugs. The president was joined by pharmaceutical executives as well as Health Secretary Robert F. Kennedy, Jr., and Centers for Medicare and Medicaid Administrator Dr. Mehmet Oz during the announcement of the newest Most Favored Nation prescription drug pricing.
The White House stated, “The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.”
The White House fact sheet explained that, when purchased through TrumpRx, “The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350” and “the price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346.”
As the Lord Leads, Pray with Us…
- For President Trump to seek God’s direction as he works to implement economic and health policies.
- For HHS Secretary Kennedy and CMS Administrator Oz as they assess the state of public health and the impacts of prescription drug pricing.
Sources: The White House, Daily Caller, ABC News
